Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies.

Science translational medicine - 28 Jan 2015

Zanella Eugenia R, Galimi Francesco, Sassi Francesco, Migliardi Giorgia, Cottino Francesca, Leto Simonetta M, Lupo Barbara, Erriquez Jessica, Isella Claudio, Comoglio Paolo M, Medico Enzo, Tejpar Sabine, Budinská Eva, Trusolino Livio, Bertotti Andrea

Abstract excerpt

Among patients with colorectal cancer who benefit from therapy targeted to the epidermal growth factor receptor (EGFR), stable disease (SD) occurs more frequently than massive regressions. Exploring the mechanisms of this incomplete sensitivity to devise more efficacious treatments will likely improve patients' outcomes. We tested therapies tailored around hypothesis-generating molecular features in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Cetuximab

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Trials as Topic

Share to Drug Resistance, Neoplasm

Share to ErbB Receptors

Share to Insulin-Like Growth Factor II

Share to Ligands

Share to Neoplasm Transplantation

Source

Identifiers

PMID: 25632036
DOI: 10.1126/scitranslmed.3010445

Genes

EGFR
IGF2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies.PMID 25632036Read ↗

Evaluating Patient-Derived Colorectal Cancer Xenografts as Preclinical Models by Comparison with Patient Clinical DataSemantic proximity Read ↗

The genomic landscape of response to EGFR blockade in colorectal cancer.Semantic proximity Read ↗

XENTURION, a multidimensional resource of xenografts and tumoroids from metastatic colorectal cancer patients for population-level translational oncologySemantic proximity Read ↗

Patient-derived xenograft (PDX) models of colorectal carcinoma (CRC) as a platform for chemosensitivity and biomarker analysis in personalized medicine.Semantic proximity Read ↗

Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitorsSemantic proximity Read ↗

A combined computational and functional approach identifies IGF2BP2 as a driver of chemoresistance in a wide array of pre-clinical models of colorectal cancerSemantic proximity Read ↗

Feedback activation of EGFR/wild-type RAS signaling axis limits KRASG12D inhibitor efficacy in KRASG12D-mutated colorectal cancer.Semantic proximity Read ↗

Insulin-Like Growth Factor 2 (IGF2) Signaling in Colorectal Cancer—From Basic Research to Potential Clinical ApplicationsSemantic proximity Read ↗

Development of a precision medicine pipeline to identify personalized treatments for colorectal cancer.Semantic proximity Read ↗

Integrative ensemble modelling of cetuximab sensitivity in colorectal cancer PDXsSemantic proximity Read ↗

IRS2 copy number gain, KRAS and BRAF mutation status as predictive biomarkers for response to the IGF-1R/IR inhibitor BMS-754807 in colorectal cancer cell lines.Semantic proximity Read ↗

Negative Ultraselection of Patients With RAS/BRAF Wild-Type, Microsatellite-Stable Metastatic Colorectal Cancer Receiving Anti–EGFR-Based TherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.